Receptor Agonist Obesity
GLP-1 does not slow Parkinson’s disease progression in phase 3 study
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study published in The Lancet.
Top in endocrinology: Tirzepatide beats semaglutide; menopausal hormone therapy and CV risk
Patients with overweight or obesity assigned tirzepatide lost more weight compared with those assigned semaglutide, according to new results from the SURMOUNT-5 trial announced by Eli Lilly.
Zepbound bests Wegovy in head-to-head weight-loss trial
Eli Lilly announced top-line results of the SURMOUNT-5 trial in which patients with overweight or obesity assigned tirzepatide lost more weight than those assigned semaglutide.
Obesity treatments may offer powerful bonus benefit: Lowering high blood pressure
The disease of obesity often brings cardiometabolic consequences, including hypertension, which remains the most potent and predictive risk factor for cardiovascular disease.